Fundus Image-guided Focal Electroretinography, Usability Study

Sponsor
Maculaser Oy (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05100511
Collaborator
(none)
20
1
2
13.9
1.4

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate the usability of fundus image-guided focal electroretinography device with healthy subjects and with macular edema and macular degeneration patients.

Condition or Disease Intervention/Treatment Phase
  • Device: ERG electrode tests for fundus image-guided focal ERG
  • Device: Fundus image-guided focal ERG
N/A

Detailed Description

In this study, we will study the usability of focal electroretinography device combined with slit lamp biomicroscope. The device allows simultaneous fundus imaging and focal ERG recording from the desired retinal area.

In phase I, the usability of the investigational device is tested with 10 healthy volunteers. The examinations include focal ERG and noise tests with commercial ERG electrodes. The stimulus lights are guided to the fundus using either non-contact of contact fundus lens. One electrode is selected for phase II based on signal-to-noise ration, usability, and comfort.

In phase II, fundus image-guided focal ERG recordings are conducted with total of 10 patients having either macular edema or macular degeneration. The aim of the phase II is to test whether the investigational device can be used to record focal ERG signal from the desired symptomatic retinal area.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Non-Randomized
Intervention Model:
Sequential Assignment
Intervention Model Description:
The usability of the investigational device is examined first with 10 healthy subjects and afterwards with total of 10 patients suffering either from macular edema or macular degeneration.The usability of the investigational device is examined first with 10 healthy subjects and afterwards with total of 10 patients suffering either from macular edema or macular degeneration.
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Fundus Image-guided Focal Electroretinography, Usability Study
Actual Study Start Date :
Nov 4, 2021
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Phase I, healthy subjects

General usability of the device is tested with healthy patients. Different commercial electroretinography electrodes are tested to investigate the patient comfort, usability and signal-to-noise ratio when recording fundus image-guided focal electroretinography with the investigational device. Most suitable electrode is selected to phase II.

Device: ERG electrode tests for fundus image-guided focal ERG
Investigate the patient comfort, usability and signal-to-noise ratio of different commercial CE marked ERG electrodes.

Experimental: Phase II, patients with macular edema or macular degeneration

The usability of the device is tested with patients suffering either from macular edema or macular degeneration. Fundus image-guided focal electroretinography is recorded with the electrode chosen in phase I from two different retinal areas: from an area with macular edema or signs of macular degeneration and from a healthy area (area without macular edema or signs of macular degeneration).

Device: Fundus image-guided focal ERG
Record focal ERG from a healthy retinal area and from an area with visible symptoms.

Outcome Measures

Primary Outcome Measures

  1. Signal-to-noise ratio of focal electroretinography signal [Through study completion, an average of 1 year]

    Signal-to-noise ratio of the focal ERG signals with different ERG electrodes.

  2. Focal ERG from symptomatic retinal area [Through study completion, an average of 1 year]

    Explore the device feasibility in recording focal ERG signal from areas with macular edema or macular degeneration.

Secondary Outcome Measures

  1. Patient comfort and usability of different ERG electrodes in focal ERG. [Through study completion, an average of 1 year]

    Investigated using a questionnaire for the subjects and investigator.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Healthy volunteers with no signs of macular edema or macular degeneration (phase I)

  • Patients with either macular edema or macular degeneration (phase II)

  • Able to give informed consent

Exclusion Criteria:
  • Epileptic patients

  • Vulnerable population: pregnant and breastfeeding women, underage, prisoners, persons with physical handicaps or mental disabilities, and disadvantaged persons.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Helsinki University Hospital, Retinal Outpatient Clinic Helsinki Uusimaa Finland 00280

Sponsors and Collaborators

  • Maculaser Oy

Investigators

  • Principal Investigator: Joni Turunen, MD, Helsinki University Central Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Maculaser Oy
ClinicalTrials.gov Identifier:
NCT05100511
Other Study ID Numbers:
  • MACULARERG01
First Posted:
Oct 29, 2021
Last Update Posted:
Nov 5, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Maculaser Oy
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 5, 2021